These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 21419775)

  • 1. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children.
    Meier S; Bel M; L'huillier A; Crisinel PA; Combescure C; Kaiser L; Grillet S; Pósfay-Barbe K; Siegrist CA;
    Vaccine; 2011 Apr; 29(19):3548-57. PubMed ID: 21419775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
    Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
    Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children.
    Scheifele DW; Ward BJ; Dionne M; Vanderkooi O; Langley JM; Dobson S; Li Y; Law B; Halperin SA;
    Pediatr Infect Dis J; 2011 May; 30(5):402-7. PubMed ID: 21178654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age.
    Roman F; Vaman T; Kafeja F; Hanon E; Van Damme P
    Clin Infect Dis; 2010 Sep; 51(6):668-77. PubMed ID: 20687838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults.
    Palma P; Romiti ML; Bernardi S; Pontrelli G; Mora N; Santilli V; Tchidjou HK; Aquilani A; Cotugno N; Alghisi F; Lucidi V; Rossi P; Douagi I
    Biologicals; 2012 Mar; 40(2):134-9. PubMed ID: 22261282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals.
    Kajaste-Rudnitski A; Galli L; Nozza S; Tambussi G; Di Pietro A; Pellicciotta G; Monti A; Mascagni P; Moro M; Vicenzi E
    AIDS; 2011 Jan; 25(2):177-83. PubMed ID: 21150561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients.
    Tremblay CL; Rouleau D; Fortin C; Toma E; Sylla M; Cyr L; Cote S; Baz M; Sampalis J; Trautman L; Sékaly RP; Boivin G
    Vaccine; 2011 Feb; 29(7):1359-63. PubMed ID: 21185423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
    Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
    Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents.
    Esposito S; Tagliaferri L; Daleno C; Valzano A; Picciolli I; Tel F; Prunotto G; Serra D; Galeone C; Plebani A; Principi N
    Vaccine; 2011 Feb; 29(8):1677-82. PubMed ID: 21199699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responses to 2009 H1N1 vaccine in children 3 to 17 years of age.
    Arguedas A; Soley C; Lindert K
    N Engl J Med; 2010 Jan; 362(4):370-2. PubMed ID: 20042746
    [No Abstract]   [Full Text] [Related]  

  • 11. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
    Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
    Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.
    Caillet C; Piras F; Bernard MC; de Montfort A; Boudet F; Vogel FR; Hoffenbach A; Moste C; Kusters I
    Vaccine; 2010 Apr; 28(18):3076-9. PubMed ID: 20193791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody response after a single dose of an AS03-adjuvanted split-virion influenza A (H1N1) vaccine in heart transplant recipients.
    Meyer S; Adam M; Schweiger B; Ilchmann C; Eulenburg C; Sattinger E; Runte H; Schlüter M; Deuse T; Reichenspurner H; Costard-Jäckle A
    Transplantation; 2011 May; 91(9):1031-5. PubMed ID: 21358365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents.
    Lu CY; Shao PL; Chang LY; Huang YC; Chiu CH; Hsieh YC; Lin TY; Huang LM
    Vaccine; 2010 Aug; 28(36):5864-70. PubMed ID: 20600484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months.
    Esposito S; Pugni L; Daleno C; Ronchi A; Valzano A; Serra D; Mosca F; Principi N
    Pediatrics; 2011 May; 127(5):e1161-8. PubMed ID: 21464195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
    Roman F; Vaman T; Gerlach B; Markendorf A; Gillard P; Devaster JM
    Vaccine; 2010 Feb; 28(7):1740-5. PubMed ID: 20034605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
    Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
    Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seasonal influenza vaccine provides priming for A/H1N1 immunization.
    Del Giudice G; Stittelaar KJ; van Amerongen G; Simon J; Osterhaus AD; Stöhr K; Rappuoli R
    Sci Transl Med; 2009 Dec; 1(12):12re1. PubMed ID: 20371459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial.
    Plennevaux E; Blatter M; Cornish MJ; Go K; Kirby D; Wali M; Reeves-Hoché MK; Denis M
    Vaccine; 2011 Feb; 29(8):1569-75. PubMed ID: 21219979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study.
    Gabay C; Bel M; Combescure C; Ribi C; Meier S; Posfay-Barbe K; Grillet S; Seebach JD; Kaiser L; Wunderli W; Guerne PA; Siegrist CA;
    Arthritis Rheum; 2011 Jun; 63(6):1486-96. PubMed ID: 21384334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.